Page last updated: 2024-11-04

sotalol and Cancer of Prostate

sotalol has been researched along with Cancer of Prostate in 2 studies

Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.

Research Excerpts

ExcerptRelevanceReference
"The study included all new prostate cancer cases diagnosed in Finland during 1995-2002 and matched controls (24,657 case-control pairs) obtained from the Finnish Cancer Registry and the Population Register Center, respectively."1.42Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study. ( Ahti, J; Auvinen, A; Kaapu, KJ; Murtola, TJ; Tammela, TL, 2015)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kaapu, KJ2
Ahti, J1
Tammela, TL2
Auvinen, A2
Murtola, TJ2
Määttänen, L1
Talala, K1
Taari, K1

Other Studies

2 other studies available for sotalol and Cancer of Prostate

ArticleYear
Sotalol, but not digoxin is associated with decreased prostate cancer risk: A population-based case-control study.
    International journal of cancer, 2015, Sep-01, Volume: 137, Issue:5

    Topics: Anti-Arrhythmia Agents; Case-Control Studies; Digoxin; Finland; Humans; Logistic Models; Male; Potas

2015
Prostate cancer risk among users of digoxin and other antiarrhythmic drugs in the Finnish Prostate Cancer Screening Trial.
    Cancer causes & control : CCC, 2016, Volume: 27, Issue:2

    Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Cohort Studies; Digoxin; Finland; Humans;

2016